Navigation Links
Applied Integrin Sciences, Inc. Announces Exceptional Results In Ovarian Cancer Study
Date:9/20/2013

NEW YORK, Sept. 20, 2013 /PRNewswire-iReach/ -- Applied Integrin Sciences, Inc. announced today that its first cancer therapeutic drug candidate eliminated all intraperitoneal ovarian cancer tumors in a pre-clinical study testing a novel treatment regimen.  Funded by the National Cancer Institute through the company's first NCI grant awarded December last year, its lead candidate drug Vicrostatin was combined with a drug-eluting gel and applied into the peritoneum for sustained release of the drug directly to ovarian cancer metastatic tumors. 

"The results our scientists achieved are exceptional", said Thomas C. Chen, MD, Ph.D., the company's Chief Medical Officer, "and suggest an equivalent human treatment for ovarian cancer patients is feasible.  The implications for this treatment are equally compelling as 75% of women first diagnosed with ovarian cancer have stage III or stage IV metastatic disease and 80% of those women fail to survive longer than 20 months post diagnosis.  This approach is early but if we are able to achieve comparable results in human clinical trials with women suffering from ovarian cancer this treatment could considerably change the current standard of care."

The company's two drug candidates previously demonstrated substantial reduced tumor growth and progression in pre-clinical testing against six aggressive cancers: triple negative breast cancer; primary prostate cancer; prostate bone metastasis; ovarian cancer; melanoma; and glioblastoma.  Both drug candidates, Vicrostatin and ADM-01, are recombinant proteins discovered by the company's founding scientists at the University of Southern California's Keck School of Medicine and Norris Comprehensive Cancer Center.  Each uniquely targets specific cell surface receptors that are activated only in actively growing cancer cells and when metastatic cells and cells producing new tumor vasculature are actively motile.  These cancer growth and progression processes are necessary for cancers to seed new metastatic tumors throughout the body and to produce the blood vasculature that is required for tumors to grow and cause death. 

The cancer fighting mechanisms of the company's two drug candidates are very unique and suggest better efficacy, improved safety, and longer sustained therapeutic effects than current cancer drugs.  The company plans to complete pre-clinical development of its lead candidate and file an Investigational New Drug application with the FDA to begin human clinical trials with funds it receives from its next round of financing.

About Applied Integrin Sciences

Applied Integrin Sciences is a pre-clinical stage biopharmaceutical company committed to discover, develop, and commercialize novel drug therapies and treatments for cancer that reduce tumor growth and progression and improve patient survival and quality of life.  The Company's Founding Scientists discovered, developed and patented a drug discovery platform to produce novel integrin-modulating recombinant protein drugs that reduce tumor growth and progression in primary tumors, newly growing vasculature, and metastatic foci. The company recruited an outstanding team of exceptional industry-experienced drug development and business executives to lead the company and its drug development program. The company is evaluating a novel treatment for ovarian cancer, an orphan indication recently funded by the National Cancer Institute, as its first indication. For additional information about the company, please visit www.integrins.com.

Source: Applied Integrin Sciences, Inc.

Olmstead Williams Communications, Inc.

(310) 824-9000

www.olmsteadwilliams.com

Media Contact: Public Relations, Applied Integrin Sciences, Inc., (805) 715-4166, info@integrins.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Applied Integrin Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. iBioLaunch™ Technology Successfully Applied to Modified C1 Inhibitor
2. GeneThera, Inc. Acquires Applied Genetics, S.A.
3. Thomas Elsaesser and Horst Weller receive the Julius Springer Prize for Applied Physics 2012
4. Applied Genetics Initiates Commercial Operation
5. Life Technologies to Accelerate Development of Ion Torrent Semiconductor Technology for Proteomic Applications in Research, Applied and Clinical Markets
6. Three Hertz Foundation Fellows Receive Presidential Honors; Leaders in Applied Physical, Biological and Engineering Sciences
7. USC Center For Applied Molecular Medicine To Honor Sumner Redstone And Murray Gell-Mann, Ph.D. At The Inaugural REBELS WITH A CAUSE Gala
8. Lucas Bagnell Varga LLC Secures $17.4 Million Award For Former Applied Biosystems Executives
9. APPLIED PHYSIOLOGY® Receives key US Patent Award for its Unique NAVIGATOR™ Technology
10. SPIE Encouraged By Increased Science Funding in Obama Budget, Urges Applied Research Emphasis
11. SPIE Appoints Ni-Bin Chang Editor of Journal of Applied Remote Sensing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... , ... January 11, 2017 , ... ... scientific grants to ground-breaking microbiome studies. Its most recent microbiome impact grant award ... who will study the effect of long-term use of oral antibiotics, prescribed for ...
(Date:1/11/2017)... , ... January 11, 2017 , ... ... make all the difference when navigating the challenges young businesses face. With the ... the extensive expertise and experience of Geoff DiMasi, Founder and Principal of interactive ...
(Date:1/11/2017)... ... January 11, 2017 , ... Back pain relief technology is now available ... Surgery for positive back pain relief for WAR members. , This spinal restoration platform ... be life changing for millions suffering from chronic back pain. , What A ...
(Date:1/11/2017)... and BENGALURU, India , Jan. ... Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced ... accepted Mylan,s biologics license application (BLA) for MYL-1401O, a ... This product is a proposed biosimilar to branded trastuzumab, ... The anticipated FDA goal date set under the Biosimilar ...
Breaking Biology Technology:
(Date:12/15/2016)... Dec 15, 2016 ... Research and Markets has announced the addition of ... The report forecasts the global military biometrics market to ... The report has been prepared based on an in-depth market analysis ... its growth prospects over the coming years. The report also includes a ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the ... market is expected to grow from USD 4.03 billion ... a CAGR of 29.3% between 2016 and 2022. The ... demand for smart devices, government initiatives, and increasing penetration ... is expected to grow at a high rate during ...
(Date:12/8/2016)... 2016  Singulex, Inc., the leader in Next Generation ... a license and supply agreement with Thermo Fisher Scientific, ... Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), a ... used to diagnose systemic bacterial infection and sepsis and ... aid in assessing the risk of critically ill patients ...
Breaking Biology News(10 mins):